Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Targeting CD47/SIRPα in Acute...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab

Bibliographic Details
Published in:Journal of Immunotherapy and Precision Oncology
Main Authors: Fadi Haddad, Naval Daver
Format: Article
Language:English
Published: Innovative Healthcare Institute 2021-05-01
Subjects:
azacitidine
magrolimab
aml
mds
cd47
Online Access:https://jipo.org/doi/pdf/10.36401/JIPO-21-X2
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://jipo.org/doi/pdf/10.36401/JIPO-21-X2

Similar Items

  • CD47–SIRPα-targeted therapeutics: status and prospects
    by: R. Maute, et al.
    Published: (2022-03-01)
  • Opportunities and challenges for anti-CD47 antibodies in hematological malignancies
    by: Yilan Xu, et al.
    Published: (2024-02-01)
  • Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
    by: Kevin Yao, et al.
    Published: (2023-03-01)
  • Tolerability and safety of magrolimab (ONO-7913) in Japanese patients with advanced or metastatic solid tumors: a phase 1, open-label, uncontrolled, dose-escalation study
    by: Takafumi Koyama, et al.
    Published: (2026-03-01)
  • Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors
    by: Antoine Italiano, et al.
    Published: (2026-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs